Purchases of vaccines for human use in Central America as of the third quarter of 2021 represented a value of $250 million, with Guatemalan companies being the main importers with $73 million.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graphic"]
For the third quarter of 2021, an increase in regional imports of vaccines for veterinary use from Central America is observed with $34 million, Guatemala being the main buyer with $11 million.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graphic"]
In the second quarter of 2022, purchases made by Salvadoran companies increased dramatically, reaching almost 500%, representing 45% of regional purchases with $67 million.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graphic"]
For the second quarter of 2021, purchases of vaccines for veterinary use remained at $23 million, the main supplier for this period was the United States with $7 million.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graphic"]
In 2020, Guatemala acquired the largest share of veterinary vaccines in the Central American market with $15.2 million, the main seller being the United States with 35.65%, equivalent to $12.4 million in the region.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graphic"]
During 2020, companies in the region allocated $134 million for the import of vaccines for human use, and purchases from Russian companies increased 54% over what was reported in 2019.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graph"]
For Fitch, the delay in vaccination campaigns constitutes a latent risk of a prolonged pandemic, which would delay the recovery of the region's economies and would cause negative pressures on the risk ratings to be issued in the coming months.
Fitch Ratings issued a bulletin for Mexico, Central America and the Caribbean on May 25, in which it warned that given the deep economic contractions in the region and the moderate recovery outlook, there are threats of negative rating pressures.
The Ministry of National Defense of Guatemala tenders the supply of 20,020 vaccines against the influenza virus, which will be applied to members of the Army.
Guatemala Government Purchase 14393417:
"General characteristics:
-Dose in 0.5 ml pre-filled syringe.
-Transparent packaging
-Smooth texture
-Colorless, opalescent liquid consistency. Injectable solution, 0.5 ml pre-filled syringe with attached needle and label with vaccine composition information. From 4 strains of the northern hemisphere.
From January to September 2020, companies in the region invested $101 million for the purchase abroad of vaccines for human use, and purchases from Russian companies increased 34% compared to the same period in 2019.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with the graph"]
During the first semester of 2020, companies from Central American countries bought abroad $23 million in vaccines for animal use, 18% more than what was reported for the same period in 2019.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with graph"]
From January to June 2020, companies in the region allocated $71 million for the purchase of human vaccines abroad, and 60% of imports were made by companies in Panama, Guatemala and Honduras.
Figures from the Trade Intelligence Area of CentralAmericaData: [GRAFICA caption="Click to interact with graphic"]
From January to March 2020, companies in the region bought vaccines for human use abroad for $28 million, and 56% of total imports were made by companies in Costa Rica and Panama.
Figures from the Trade Intelligence Unit of CentralAmericaData: [GRAFICA caption="Click to interact with graphic"]
From January to September 2019, companies in the region bought vaccines for human use abroad for $154 million, 56% more than what was reported for the same period in 2018, a rise that is mainly explained by the behavior of imports in Panama.
Figures from the Trade Intelligence Unit at CentralAmericaData: [GRAFICA caption="Click to interact with graphics"]
During the first semester of 2019, companies from Central American countries bought $20 million in vaccines for animal use abroad, and 55% was imported by companies in Guatemala and Costa Rica.
Figures from the Trade Intelligence Unit at CentralAmericaData: [GRAFICA caption="Click to interact with graphics"]
In the first half of 2019, purchases of vaccines for human use in Central America totaled $122 million, 116% more than was reported in the same period in 2018.
Figures from the Trade Intelligence Unit at CentralAmericaData: [GRAPHIC caption="Click to interact with graphic"]